DKSH Healthcare has expanded its strategic partnership with Novartis in South Korea by adding the hypertension medicines Diovan® and Exforge® to its prescription drug portfolio. Under the agreement, DKSH Korea will manage local sales, medical affairs and marketing activities for both products, strengthening its presence in the country's prescription medicines market.

The collaboration builds on DKSH Korea's existing prescription portfolio, which includes AstraZeneca's hypertension treatment Atacand and haematology and nephrology products from Kyowa Kirin. The agreement further reinforces the company's position in the Korean pharmaceutical market and supports the continued expansion of its healthcare business.

Diovan and Exforge are established treatments for hypertension that have been widely used in cardiology departments and primary care settings across South Korea. DKSH Korea plans to use its existing commercial, medical and marketing capabilities to expand the market presence of both medicines.

As part of the partnership, the company also intends to recruit additional professionals with expertise in the products and the local pharmaceutical market to support the continued growth of its prescription drug business.

The expanded agreement reflects DKSH's strategy of strengthening access to prescription medicines through partnerships with pharmaceutical companies while enhancing its commercial capabilities in South Korea.

 

Source: dksh.com

Report Abuse